Prev Close | 35.25 |
Day Low/High | 32.97 / 35.50 |
52 Wk Low/High | 9.00 / 56.50 |
Prev Close | 35.25 |
Day Low/High | 32.97 / 35.50 |
52 Wk Low/High | 9.00 / 56.50 |
Exchange | NASDAQ |
Shares Outstanding | 376.84B |
Market Cap | 13.28B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Remember this: the market's often wrong.
Traders should look to buy available weakness into the $12-$11 area.
They really do not have very high hopes for the short to medium term future. Yet, the market buys their news.
The Russell 2000 has now soared 16% year to date, nearly twice the Nasdaq Composite's 8.5% move.
CSCO is edging toward a major breakout level. Let's check the charts.
Shares of the cannabis stock have recently strengthened.
Here's how to play CGC.
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Georgia's election results have given the industry a big green light, meaning positive moves are expected out of cannabis stocks.
Let's take a fresh look at the charts and indicators.
Continue to hold longs in previous recommendations.
If Democrats score, marijuana names could benefit.
Aphria investors will have a larger stake in the combined company post-merger.
This is the first time that any cannabis bill addressing descheduling has been approved by Congress.
There were several reasons why the 2020 supply fell from 2019 levels.
Traders could approach CGC from the long side.
A 'green wave' has advanced cannabis legalization across America. And that's just one of the forces powering up pot stocks right now.
Collective Growth Corp is the first and largest SPAC focused on building the U.S. commercial hemp supply chain.
Can corporate America grow sales for the fourth quarter? Then answer a question with a question.
Let's review the charts of this cannabis firm to see if a sustained advance is ready to begin.
The potential of legal New York adult-use cannabis sales have been estimated at $1.5 billion a year by 2023.
Cannabis investors are keenly aware of the landscape and how it could play out for the industry.
Let's take a close look at Canopy Growth, GrowGeneration and cannabis REIT Innovative Industrial Properties.
Just as we saw with pot stocks, if you play shares strictly because they're going up, you're likely to get burnt.
Ayr Strategies is expanding in a contracting market.
The amended deal between the two cannabis companies is a doozy.
I continue to recommend a reduced long exposure on STZ.
Publicly traded cannabis companies are expected to take big write downs on assets, and here's why it matters.